Salvadori S, Attila M, Balboni G, Bianchi C, Bryant S D, Crescenzi O, Guerrini R, Picone D, Tancredi T, Temussi P A
Department of Pharmaceutical Sciences, University of Ferrara, Italy.
Mol Med. 1995 Sep;1(6):678-89.
Tyr-Tic (1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) and Tyr-Tic-Ala were the first peptides with delta opioid antagonist activity lacking Phe, considered essential for opioid activity based on the N-terminal tripeptide sequence (Tyr-D-Xaa-Phe) of amphibian skin opioids. Analogs were then designed to restrain the rotational flexibility of Tyr by the substitution of 2,6-dimethyl-L-tyrosine (Dmt).
Tyr and Dmt peptides were synthesized by solid phase and solution methods using Fmoc technology or condensing Boc-Dmt-OH or Boc-Tyr(But)-OH with H-L-Tic-OBut or H-D-Tic-OBut, respectively. Peptides were purified (> 99%) by HPLC and characteristics determined by 1H-NMR, FAB-MS, melting point, TLC, and amino acid analyses.
H-Dmt-Tic-OH had high affinity (Ki delta = 0.022 nM) and extraordinary selectivity (Ki mu/Ki delta = 150,000); H-Dmt-Tic-Ala-OH had a Ki delta = 0.29 nM and delta selectivity = 20,000. Affinity and selectivity increased 8700- and 1000-fold relative to H-Tyr-Tic-OH, respectively. H-Dmt-Tic-OH and H-Dmt-Tic-NH2 fitted one-site receptor binding models (eta = 0.939-0.987), while H-Dmt-Tic-ol, H-Dmt-Tic-Ala-OH and H-Dmt-Tic-Ala-NH2 best fitted two-site models (eta = 0.708-0.801, F 18.9-26.0, p < 0.0001). Amidation increased mu affinity by 10- to 100-fold and acted synergistically with D-Tic2 to reverse selectivity (delta-->mu). Dmt-Tic di- and tripeptides exhibited delta antagonist bioactivity (Ke = 4-66 nM) with mouse vas deferens and lacked agonist mu activity (> 10 microM) in guinea-pig ileum preparations. Dmt-Tic analogs weakly interacted with kappa receptors in the 1 to > 20 microM range.
Dmt-Tic opioidmimetic peptides represent a highly potent class of opioid peptide antagonists with greater potency than the nonopioid delta antagonist naltrindole and have potential application as clinical and therapeutic compounds.
酪氨酰-替可汀(1,2,3,4-四氢异喹啉-3-羧酸)和酪氨酰-替可汀-丙氨酸是首批具有δ阿片样物质拮抗剂活性且不含苯丙氨酸的肽类,基于两栖类皮肤阿片样物质的N端三肽序列(酪氨酰-D-Xaa-苯丙氨酸),苯丙氨酸被认为对阿片样物质活性至关重要。随后设计了类似物,通过用2,6-二甲基-L-酪氨酸(Dmt)取代来限制酪氨酰的旋转灵活性。
使用Fmoc技术通过固相和溶液法合成酪氨酰和Dmt肽,分别将Boc-Dmt-OH或Boc-酪氨酰(叔丁酯)-OH与H-L-替可汀-叔丁酯或H-D-替可汀-叔丁酯缩合。肽通过高效液相色谱法纯化(>99%),并通过1H-NMR、快原子轰击质谱、熔点、薄层色谱和氨基酸分析确定其特性。
H-Dmt-替可汀-OH具有高亲和力(Kiδ = 0.022 nM)和非凡的选择性(Kiμ/Kiδ = 150,000);H-Dmt-替可汀-丙氨酸-OH的Kiδ = 0.29 nM,δ选择性 = 20,000。相对于H-酪氨酰-替可汀-OH,亲和力和选择性分别增加了8700倍和1000倍。H-Dmt-替可汀-OH和H-Dmt-替可汀-NH2符合单点受体结合模型(η = 0.939 - 0.987),而H-Dmt-替可汀醇、H-Dmt-替可汀-丙氨酸-OH和H-Dmt-替可汀-丙氨酸-NH2最符合双点模型(η = 0.708 - 0.801,F 18.9 - 26.0,p < 0.0001)。酰胺化使μ亲和力增加10至100倍,并与D-替可汀2协同作用以逆转选择性(δ→μ)。Dmt-替可汀二肽和三肽在小鼠输精管中表现出δ拮抗剂生物活性(Ke = 4 - 66 nM),在豚鼠回肠制剂中缺乏激动剂μ活性(>10 μM)。Dmt-替可汀类似物在1至>20 μM范围内与κ受体弱相互作用。
Dmt-替可汀类阿片样模拟肽代表一类高效的阿片样肽拮抗剂,其效力高于非阿片样δ拮抗剂纳曲吲哚,具有作为临床和治疗化合物的潜在应用价值。